Literature DB >> 8591887

Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats.

P Sventek1, J S Li, K Grove, C F Deschepper, E L Schiffrin.   

Abstract

Inhibition of nitric oxide synthase by L-arginine analogues is associated with elevation of blood pressure in rats. Deoxycorticosterone acetate (DOCA)-salt hypertensive rats and DOCA-salt-treated spontaneously hypertensive rats (SHR) overexpress the endothelin-1 gene in blood vessels, and this is associated with severe vascular hypertrophy, whereas SHR do not overexpress endothelin-1 and exhibit limited vascular hypertrophy. In this study malignant hypertension was induced in SHR by chronic administration of the L-arginine analogue NG-nitro-L-arginine methyl ester (L-NAME), a potent inhibitor of nitric oxide synthase, to determine whether malignant hypertension would result in endothelin-1 gene overexpression in blood vessels and in greater severity of vascular hypertrophy, as found in malignant DOCA-salt-treated SHR. L-NAME treatment induced malignant hypertension in SHR, with a systolic blood pressure of 246 +/- 2 mm Hg, compared with 211 +/- 2 mm Hg (P < .01) in untreated SHR. Plasma renin activity was very high in L-NAME-treated SHR, and their plasma immunoreactive endothelin concentration was slightly but significantly elevated (P < .01). After 3 weeks of treatment, aortic and to a lesser degree mesenteric artery weights were significantly increased in L-NAME-treated SHR compared with untreated SHR. However, cardiac weight and the media cross-sectional area or media width-to-lumen diameter ratio of small arteries from the coronary, renal, mesenteric, or femoral vasculature were not increased in L-NAME-treated SHR in comparison with untreated SHR. The abundance of endothelin-1 mRNA measured by Northern blot analysis was significantly increased in L-NAME-treated SHR in aorta and with less magnitude in the mesenteric arterial tree. The absence of accentuation of cardiac and small artery hypertrophy in malignant hypertension in L-NAME-treated SHR, despite enhanced expression of the endothelin-1 gene in blood vessels, may suggest a direct or indirect inhibitory effect of L-NAME on cardiovascular growth, probably independent of its effects on nitric oxide synthase, counterbalanced in aorta and large mesenteric arteries by the hypertrophic effect of enhanced vascular endothelin-1 gene expression. These results also suggest a role for blood pressure and potentially for nitric oxide in the regulation of endothelin-1 gene expression in blood vessels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8591887     DOI: 10.1161/01.hyp.27.1.49

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  Angiotensin II and nitric oxide interaction.

Authors:  Marc de Gasparo
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 3.  Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.

Authors:  Agustin Gonzalez-Vicente; Fara Saez; Casandra M Monzon; Jessica Asirwatham; Jeffrey L Garvin
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

4.  Endothelin Receptor A Antagonism and Fetal Growth in Endothelial Nitric Oxide Synthase Gene Knockout Maternal and Fetal Mice.

Authors:  Kehuan Luo; Larry G Thaete; Mark G Neerhof
Journal:  Reprod Sci       Date:  2016-01-19       Impact factor: 3.060

5.  Altered endothelin receptor binding in response to nitric oxide synthase inhibition in the pregnant rat.

Authors:  Mark G Neerhof; Tamas Jilling; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Reprod Sci       Date:  2008-03-06       Impact factor: 3.060

6.  Resveratrol Protects Cardiac Tissue in Experimental Malignant Hypertension Due to Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Properties.

Authors:  Jelica Grujić-Milanović; Vesna Jaćević; Zoran Miloradović; Djurdjica Jovović; Ivica Milosavljević; Sladjan D Milanović; Nevena Mihailović-Stanojević
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.